Shareholders of Novo Nordisk are pressing the pharmaceutical giant to increase its pace of dealmaking and expand its portfolio of new medications, according to a report by the Financial Times.
The call comes from investors seeking to ensure the company maintains its competitive edge and continues to grow beyond its current blockbuster products. The feedback underscores mounting expectations for Novo Nordisk to diversify its pipeline through strategic acquisitions and internal research.
While specific details of the investors’ demands were not fully elaborated in the source material, the general sentiment reflects a broader trend among major stakeholders in the pharmaceutical sector who are looking for aggressive expansion strategies to secure future revenue streams.
Is this realistic though? The pipeline is already crowded. More acquisitions just mean higher debt and integration headaches.
Finally, some pressure to stop resting on their obesity drug laurels. Diversification is key for long-term survival.